2  HPTN LEADERSHIP ......................................................................................................................... 2
   2.1 HPTN Principal Investigators ................................................................................................. 2
   2.2 Executive Committee .............................................................................................................. 2
       2.2.1 Membership .................................................................................................................. 3
   2.3 HPTN Leadership Group ......................................................................................................... 3
2 HPTN LEADERSHIP

2.1 HPTN Principal Investigators

The HPTN Principal Investigators (PIs) are the leaders of the entire Network and also serve as the PIs of the Leadership and Operations Center (LOC). The PIs are responsible for ensuring the efficient development and implementation of the HPTN research agenda as well as managing the Network and coordinating activities across the three Central Resource groups: the LOC, Laboratory Center (LC), and Statistical and Data Management Center (SDMC).

The chairmanship of the HPTN Executive Committee (EC) will be held by one PI for the first three years (administrative PI), followed by the other PI. The function of the chair is to:

- Coordinate and facilitate HPTN EC responsibilities, including development and implementation of the HPTN research agenda
- Schedule and chair regular and special meetings and conferences calls of the HPTN EC and communicate the decisions and action items to HPTN investigators
- Ensure coordination of Network activities across Central Resources and provide regular and effective communications with the Clinical Trials Unit (CTU)/Clinical Research Site (CRS) Investigators

A special election of the voting members shall be held if it becomes necessary to replace either or both of the Network PIs ahead of schedule. The rotation of the network PIs at three years will start the selection process for the new PIs. This will allow a continuum of leadership that is consistent, yet changing.

2.2 Executive Committee

The HPTN EC, under the direction of the HPTN PIs, with the assistance of the relevant institutes at the United States (US) National Institutes of Health (NIH), sets the research priorities of the HPTN and directs its scientific activities. The HPTN EC:

- Sets the overall HPTN research agenda
- Reviews Scientific Committees (SCs)/Working Groups (WGs) research plans including the review and prioritization of concepts, assess study progress and contingency planning
- Evaluates and recommends the distribution of resources among the different components of the Network
- Recommends to National Institute of Allergy and Infectious Diseases (NIAID) that funds be released for specific protocol implementation
- Approves policies and procedures of the HPTN, including the governing structure and membership of standing committees
- Reviews and approves protocol leadership
- Approves study site selection
- Establishes key standing Network committees (for example, Science Review Committee, Performance Evaluation Committee, Manuscript Review Committee)
- Reviews and resolves site-related issues as needed
- Pursues new partnerships and funding opportunities
- Ensures that community and site representatives’ feedback is considered
The HPTN EC, in conjunction with NIH, determines the overall research capacity and capability for the HPTN, as well as the capacity of individual CTUs and CRSs or other sites. With members serving as liaisons to each SC/WG, the HPTN EC will ensure that the specific areas of prevention science addressed by SCs/WGs are effectively coordinated and are aligned with the priority areas. The HPTN EC will delegate the management of certain functions (e.g., protocol review, monitoring the study during implementation) to the oversight committees as described below. The structure and composition of all SCs and WGs is described in Section 4. All committees are ultimately accountable to the HPTN EC.

The HPTN EC conducts conference calls at least monthly and holds in-person (or virtual) meetings at least annually. The table below shows both voting and non-voting membership. A quorum, defined as two-thirds of the voting membership, must be present for key decisions and votes to be taken.

### 2.2.1 Membership

The HPTN EC membership includes representatives from the LOC, the SDMC, the LC, community, CRS and NIH. Representatives of the CRSs may rotate off the HPTN EC every two years.

When new members are solicited, all CRS nominees will submit a brief biosketch to the HPTN EC administrator or designee. Biosketches for nominees will be compiled, attached to the voting ballot and sent to HPTN EC members. HPTN EC members will be asked to vote for their top two choices, indicating first and second choice. Votes will be collated. If a nominee receives a majority vote, she/he will be elected. If not, the list will be narrowed down to the top three candidates and another vote will take place.

<table>
<thead>
<tr>
<th>Voting Members</th>
<th>Nonvoting Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI (Administrative), Network</td>
<td>Finance Manager, LOC</td>
</tr>
<tr>
<td>PI, Network</td>
<td>Deputy Director, LC</td>
</tr>
<tr>
<td>Non-US Lead Investigator</td>
<td>Co-Director, LC</td>
</tr>
<tr>
<td>Past PI, Network</td>
<td>Associate Director, SDMC</td>
</tr>
<tr>
<td>Past Co-PI, Network</td>
<td>HPTN Investigator Representatives</td>
</tr>
<tr>
<td>PI, LC</td>
<td></td>
</tr>
<tr>
<td>PI SDMC</td>
<td></td>
</tr>
<tr>
<td>Director, LOC</td>
<td></td>
</tr>
<tr>
<td>Community Representative</td>
<td></td>
</tr>
<tr>
<td>2 Site Representatives</td>
<td></td>
</tr>
<tr>
<td>2 Representatives from NIH</td>
<td></td>
</tr>
</tbody>
</table>

### 2.3 HPTN Leadership Group

A subset of the HPTN EC (without the NIH representatives) and members of the Central Resource groups meet routinely to discuss operational and fiscal issues related to the ongoing studies and provide timely feedback to the study teams.